Elsevier

Clinical Therapeutics

Volume 23, Issue 12, December 2001, Pages 1999-2010
Clinical Therapeutics

Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes

https://doi.org/10.1016/S0149-2918(01)80152-1Get rights and content

Abstract

Background: It has been reported that a statistically greater percentage of patients initially treated with losartan, an angiotensin II receptor antagonist (AIIA), stayed on therapy at 1 year compared with patients treated with antihypertensive drugs from other classes.

Objective: The purpose of this study was to determine whether the stay-on-therapy (persistence) patterns observed in the previous analysis were maintained over a 4-year period.

Methods: We investigated a subgroup of 15,175 hypertensive patients from an earlier studied cohort who were continuously eligible for benefits over a 4-year follow-up period. A linear regression model was developed to test the statistical significance of differences in the percentage of patients staying on therapy from 12 months to 48 months for the different antihypertensive classes.

Results: From 12 to 48 months, there was a slow continuous decline in persistence that was similar across all classes of antihypertensive medications. A greater percentage of patients treated with an AIIA (losartan) stayed on therapy from 12 to 48 months compared with patients treated with angiotensin-converting enzyme inhibitors (67.4% vs 60.7% at 12 months, P < 0.01; 50.9% vs 46.5% at 48 months, P = 0.095), calcium antagonists (67.4% vs 54.1% at 12 months, P < 0.01; 50.9% vs 40.7% at 48 months, P < 0.03), beta-blockers (67.4% vs 45.6% at 12 months, P < 0.01; 50.9% vs 34.7% at 48 months, P < 0.03), or thiazide diuretics (67.4% vs 20.8% at 12 months, P < 0.01; 50.9% vs 16.4% at 48 months, P < 0.03). The percentage of patients staying on AIIA therapy from 12 months to 48 months was statistically greater (P < 0.001) than the percentage of patients staying on therapy with other antihypertensive drug classes.

Conclusions: This analysis supports the observation that initiation of antihypertensive therapy with an AIIA such as losartan results in a greater persistence rate over a 4-year period than does therapy with any other antihypertensive class. These findings may have important implications for blood pressure control, reduction of cardiovascular risks, and health care resource utilization.

References (31)

  • RB Haynes

    Management of patient compliance in the treatment of hypertension

    Hypertension

    (1982)
  • BM Psaty et al.

    Temporal patterns of antihypertensive medication use among elderly patients

    JAMA

    (1993)
  • JK Jones et al.

    Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population

    Br Med J

    (1995)
  • JS McCombs et al.

    The costs of interrupting anti-hypertensive drug therapy in a Medicaid population

    Med Care

    (1994)
  • JM Flack et al.

    Benefits of adherence to anti-hypertensive drug therapy

    Eur Heart J

    (1996)
  • Cited by (0)

    This paper was presented in part at the meeting of the American Society of Hypertension, San Francisco, California, May 17, 2001.

    View full text